OUR PROGRAMS

TERN-701 is Terns’ proprietary, allosteric BCR-ABL TKI, designed to target the ABL myristoyl pocket, which is in development for the treatment of chronic myeloid leukemia (CML), a form of cancer that begins in the bone marrow

• Recently approved allosteric BCR-ABL TKI has demonstrated significant (~2x) efficacy improvement compared to second generation standard-of-care active site inhibitors

TERN-701 is out-licensed to Hansoh Pharmaceutical Group Company Limited for development in the greater China region (referred to as HS-10382 by Hansoh); Terns retains all worldwide development and commercialization rights outside of greater China, as well as access to data generated by Hansoh in China

A Phase 1 trial of TERN-701 in CML patients in China has been initiated by Hansoh, with patient dosing currently underway; Hansoh is responsible for all development and commercialization-related activities in greater China

In October 2023, Terns initiated the Phase 1 CARDINAL trial of TERN-701 in the United States, a global, multicenter, open-label, two-part Phase 1 clinical trial to evaluate the safety, pharmacokinetics, and efficacy of TERN-701 in participants with previously treated CML

• Patient screening is anticipated to begin in December 2023, with initial data expected in the second half of 2024

In March 2024, the United States Food and Drug Administration (FDA) granted Orphan Drug Designation for TERN-701 for the treatment of chronic myeloid leukemia

TERN-601 is an oral small-molecule glucagon-like peptide-1 receptor, or GLP-1R, agonist in development for the treatment of obesity

• Terns screened over 20,000 molecular permutations through its proprietary quantitative structure activity relationship (QSAR) model to identify suitable small-molecule scaffolds with potentially improved properties relative to other GLP-1-based approaches

Terns has identified structures believed to be suitable for oral administration as a single-agent or in combination with other drug candidates within its pipeline

In November 2023, Terns announced that the first participant was dosed in the Phase 1 clinical trial of TERN-601, the company’s lead GLP-1R development candidate

• The Phase 1 trial is a randomized, double-blind, placebo-controlled, two-part, single and multiple-ascending dose (SAD and MAD) trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of TERN-601 in healthy adults with obesity or who are overweight

• Top-line, proof of concept 28-day weight loss data from Part 2 (MAD) are expected in the second half of 2024

TERN-501 is a thyroid hormone receptor beta (THR-β) agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β compared to other THR-β agonists in development.

Preclinical studies have demonstrated that low-doses of TERN-501 achieved complete resolution of steatosis and reductions in serum lipids and hepatic inflammation and fibrosis. TERN-501 is 23-fold more selective for THR-β than for THR-α activation thereby minimizing the risk of cardiotoxicity and other off-target effects associated with non-selective THR stimulation. TERN-501 has been designed to be metabolically stable and therefore is expected to have little pharmacokinetic variability and a low clinical dose, making it an attractive candidate for use in fixed-dose combinations for NASH treatment.

In November 2023, Terns presented top-line data from the Phase 2a DUET trial of TERN-501 in a late-breaking oral presentation at AASLD’s The Liver Meeting

• TERN-501 was evaluated alone and in combination with the company’s liver-distributed farnesoid X receptor (FXR) agonist TERN-101

• Phase 2a DUET trial achieved all primary and secondary efficacy endpoints with a differentiated safety profile

We received Fast Track designation from the FDA for TERN-501 for the treatment of NASH in June 2021

Terns is combining internal chemistry expertise with external synthesis teams to develop initial set of 800 series compounds based on improving known scaffolds

We are supplementing efforts with a computational approach to virtually screen 9 billion compounds in silico to identify additional GIPR modulators, focusing on ones that can be combined with approved GLP1s

IND enabling studies expected to start in 2024